Better risk stratification, more tolerable regimens, and outcome measures beyond culture conversion top the list of unmet needs Dr. Losier identifies for MAC and NTM pulmonary disease heading into ATS 2026.
AJMC Post Conference Perspectives: Advances in MAC Pulmonary Disease From ATS 2026
New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients.
Advertisement
Advertisement
Trending on AJMC
1
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
2
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
3
Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis
4
FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera
5